Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists

被引:132
作者
Tabrizi, Mojgan Aghazadeh [1 ]
Baraldi, Pier Giovanni [1 ]
Baraldi, Stefania [1 ]
Gessi, Stefania [2 ]
Merighi, Stefania [2 ]
Borea, Pier Andrea [2 ]
机构
[1] Univ Ferrara, Dept Chem & Pharmaceut Sci, Via Fossato di Mortara 17-19, I-44121 Ferrara, Italy
[2] Univ Ferrara, Sect Pharmacol, Dept Med Sci, I-44121 Ferrara, Italy
关键词
transient receptor potential vanilloid 1; pathophysiology; TRPV1; antagonists; medicinal chemistry; structure-activity relationships; POTENTIAL VANILLOID 1; PROTEIN-KINASE-C; ACTIVATED ION-CHANNEL; LONG-TERM DEPRESSION; DIET-INDUCED OBESITY; NERVE GROWTH-FACTOR; CAPSAICIN RECEPTOR; IN-VITRO; SENSORY NEURONS; BODY-TEMPERATURE;
D O I
10.1002/med.21427
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Transient receptor potential vanilloid 1 (TRPV1) is an ion channel expressed on sensory neurons triggering an influx of cations. TRPV1 receptors function as homotetramers responsive to heat, proinflammatory substances, lipoxygenase products, resiniferatoxin, endocannabinoids, protons, and peptide toxins. Its phosphorylation increases sensitivity to both chemical and thermal stimuli, while desensitization involves a calcium-dependent mechanism resulting in receptor dephosphorylation. TRPV1 functions as a sensor of noxious stimuli and may represent a target to avoid pain and injury. TRPV1 activation has been associated to chronic inflammatory pain and peripheral neuropathy. Its expression is also detected in nonneuronal areas such as bladder, lungs, and cochlea where TRPV1 activation is responsible for pathology development of cystitis, asthma, and hearing loss. This review offers a comprehensive overview about TRPV1 receptor in the pathophysiology of chronic pain, epilepsy, cough, bladder disorders, diabetes, obesity, and hearing loss, highlighting how drug development targeting this channel could have a clinical therapeutic potential. Furthermore, it summarizes the advances of medicinal chemistry research leading to the identification of highly selective TRPV1 antagonists and their analysis of structure-activity relationships (SARs) focusing on new strategies to target this channel. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:936 / 983
页数:48
相关论文
共 305 条
[1]   Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line: implications for respiratory virus-induced cough reflex sensitivity [J].
Abdullah, H. ;
Heaney, L. G. ;
Cosby, S. L. ;
McGarvey, L. P. A. .
THORAX, 2014, 69 (01) :46-U59
[2]   Voltage-dependent priming of rat vanilloid receptor: effects of agonist and protein kinase C activation [J].
Ahern, GP ;
Premkumar, LS .
JOURNAL OF PHYSIOLOGY-LONDON, 2002, 545 (02) :441-451
[3]   Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain [J].
Akbar, Ayesha ;
Yiangou, Yiangos ;
Facer, Paul ;
Brydon, W. G. ;
Walters, Julian R. F. ;
Anand, Praveen ;
Ghosh, Subrata .
GUT, 2010, 59 (06) :767-774
[4]   Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet β cells modulates insulin secretion in rats [J].
Akiba, Y ;
Kato, S ;
Katsube, K ;
Nakamura, M ;
Takeuchi, K ;
Ishii, H ;
Hibi, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 321 (01) :219-225
[5]   Protease-activated receptors: protease signaling in the gastrointestinal tract [J].
Amadesi, S ;
Bunnett, N .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (06) :551-556
[6]   Transient receptor potential channels in bladder function [J].
Avelino, A. ;
Charrua, A. ;
Frias, B. ;
Cruz, C. ;
Boudes, M. ;
de Ridder, D. ;
Cruz, F. .
ACTA PHYSIOLOGICA, 2013, 207 (01) :110-122
[7]   Vanilloid receptor 1 expression in the rat urinary tract [J].
Avelino, A ;
Cruz, C ;
Nagy, I ;
Cruz, F .
NEUROSCIENCE, 2002, 109 (04) :787-798
[8]   TRP channels: Emerging targets for respiratory disease [J].
Banner, Katharine Helen ;
Igney, Frederik ;
Poll, Chris .
PHARMACOLOGY & THERAPEUTICS, 2011, 130 (03) :371-384
[9]  
Baraldi P. G., 2008, Preparation of N-aryl biarylcarboxamides as vanilloid-1 receptor modulators, Patent No. [WO 2008/006480, 2008006480]
[10]  
Baraldi PG, 2008, Patent Application, Patent No. [WO2008006481, 2008006481]